707 related articles for article (PubMed ID: 30809307)
21. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
[TBL] [Abstract][Full Text] [Related]
22. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
23. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.
Sha MQ; Zhao XL; Li L; Li LH; Li Y; Dong TG; Niu WX; Jia LJ; Shao RG; Zhen YS; Wang Z
Cell Death Dis; 2016 Nov; 7(11):e2486. PubMed ID: 27882937
[TBL] [Abstract][Full Text] [Related]
24. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
[TBL] [Abstract][Full Text] [Related]
25. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
26. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
[TBL] [Abstract][Full Text] [Related]
27. TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer.
Fu HL; Ma Y; Lu LG; Hou P; Li BJ; Jin WL; Cui DX
J Biomed Nanotechnol; 2014 Jul; 10(7):1217-30. PubMed ID: 24804542
[TBL] [Abstract][Full Text] [Related]
28. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
29. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
[TBL] [Abstract][Full Text] [Related]
30. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
31. GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells.
Xiong X; Zhang J; Li A; Dai L; Qin S; Wang P; Liu W; Zhang Z; Li X; Liu Z
Cancer Biol Ther; 2020; 21(3):213-222. PubMed ID: 31651209
[TBL] [Abstract][Full Text] [Related]
32. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
33. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
34. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Smoots SG; Schreiber AR; Jackson MM; Bagby SM; Dominguez ATA; Dus ED; Binns CA; MacBeth M; Whitty PA; Diamond JR; Pitts TM
Breast Cancer Res; 2024 Mar; 26(1):35. PubMed ID: 38429789
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.
Yomtoubian S; Lee SB; Verma A; Izzo F; Markowitz G; Choi H; Cerchietti L; Vahdat L; Brown KA; Andreopoulou E; Elemento O; Chang J; Inghirami G; Gao D; Ryu S; Mittal V
Cell Rep; 2020 Jan; 30(3):755-770.e6. PubMed ID: 31968251
[TBL] [Abstract][Full Text] [Related]
36. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
[TBL] [Abstract][Full Text] [Related]
37. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
39. Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progression by suppressing EZH2-mediated epigenetically silencing of p21 in triple-negative breast cancer cells.
Wu JY; Chien YC; Tsai IC; Hung CC; Huang WC; Liu LC; Yu YL
Aging (Albany NY); 2021 May; 13(9):12514-12525. PubMed ID: 33934088
[TBL] [Abstract][Full Text] [Related]
40. EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress.
Zhang R; Li X; Liu Z; Wang Y; Zhang H; Xu H
Cancer Cell Int; 2020; 20():175. PubMed ID: 32477007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
